Prostaglandin E 2 induces fibroblast apoptosis by modulating multiple survival pathways
Open accessThe DOI matches its Crossref record; 60 of the 60 references it cites were found in a registry or an index.
Abstract
Although the lipid mediator prostaglandin E(2) (PGE(2)) exerts antifibrotic effects by inhibiting multiple fibroblast functions, its ability to regulate fibroblast survival is unknown. Here, we examined the effects of this prostanoid on apoptosis and apoptosis pathways in normal and fibrotic lung fibroblasts. As compared to medium alone, 24 h of treatment with PGE(2) increased apoptosis of normal lung fibroblasts in a dose-dependent manner (EC(50) approximately 50 nM), as measured by annexin V staining, caspase 3 activity, cleavage of poly-ADP-ribose polymerase, and single-stranded DNA levels. PGE(2) also potentiated apoptosis elicited by Fas ligand plus cycloheximide. These proapoptotic actions were dependent on signaling through the EP2/EP4 receptors and by downstream activation of both caspases 8 and 9. Silencing and gene deletion of PTEN demonstrated that the effects of PGE(2) involved decreased activity of the prosurvival molecule Akt. PGE(2) also down-regulated expression of survivin, an inhibitor of apoptosis, and increased expression of Fas. Fibroblasts from patients with pulmonary fibrosis exhibited resistance to the apoptotic effects of PGE(2). These findings show for the first time that, in contrast to its effects on many other cell types, PGE(2) promotes apoptosis in lung fibroblasts through diverse pathways. They provide another dimension by which PGE(2) may inhibit, and perhaps even reverse, fibrogenesis in patients with interstitial lung disease.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Prostaglandin E2 has similar effects on formation and apoptosis in lung and keloid fibroblasts (145–147).”
From Unraveling SSc Pathophysiology; The Myofibroblast (2018) · cites this paper as [145]
Citations
Cites
Thornberry, N. A., & Lazebnik, Y. (1998) · Science · doi:10.1126/science.281.5381.1312 · Cited by 6,887
Akt Promotes Cell Survival by Phosphorylating and Inhibiting a Forkhead Transcription Factor
Brunet, A., Bonni, A., Zigmond, M. J., Lin, M. Z., Juo, P., Hu, L. S., Anderson, M. J., Arden, K. C., Blenis, J., & Greenberg, M. E. (1999) · Cell · doi:10.1016/s0092-8674(00)80595-4 · Cited by 5,594 · cited 1×
“PIP3 is a lipid mediator that recruits and activates proteins with pleckstrin homology domains such as Akt, which has been shown to be an important prosurvival mediator (41) that can inhibit both the intrinsic (42) and extrinsic (43) apoptotic pathways.”
BackgroundDanial, N. N., & Korsmeyer, S. J. (2004) · Cell · doi:10.1016/s0092-8674(04)00046-7 · Cited by 4,651
Maehama, T., & Dixon, J. E. (1998) · Journal of Biological Chemistry · doi:10.1074/jbc.273.22.13375 · Cited by 3,104 · cited 3×
“PTEN is a lipid phosphatase that antagonizes the phosphatidylinositol-3-kinase (PI3K) pathway by dephosphorylating phosphatidylinositol 3,4,5-trisphosphate (PIP3) (40).”
BackgroundMitochondrial control of cell death
Kroemer, G., & Reed, J. C. (2000) · Nature Medicine · doi:10.1038/74994 · Cited by 3,103 · cited 1×
“with activation of the apoptosome complex containing caspase 9, which leads to further cleavage of downstream effector caspases 3, 6, and 7 (35).”
BackgroundRegulation of Cell Death Protease Caspase-9 by Phosphorylation
Cardone, M. H., Roy, N., Stennicke, H. R., Salvesen, G. S., Franke, T. F., Stanbridge, E., Frisch, S., & Reed, J. C. (1998) · Science · doi:10.1126/science.282.5392.1318 · Cited by 2,481 · cited 1×
“PIP3 is a lipid mediator that recruits and activates proteins with pleckstrin homology domains such as Akt, which has been shown to be an important prosurvival mediator (41) that can inhibit both the intrinsic (42) and extrinsic (43) apoptotic pathways.”
BackgroundSelman, M., King, T. E., & Pardo, A. (2001) · Annals of Internal Medicine · doi:10.7326/0003-4819-134-2-200101160-00015 · Cited by 1,786
Desmoulière, A., Redard, M., Darby, I. A., & Gabbiani, G. (1995) · Europe PMC (PubMed Central) · Cited by 1,448
Overview of cell death signaling pathways
Jin, Z., & El-Deiry, W. S. (2005) · Cancer Biology & Therapy · doi:10.4161/cbt.4.2.1508 · Cited by 1,326 · cited 1×
“, Fas), which, in turn, triggers the formation of the death-induced signaling complex, which leads to activation of caspase 8 (36, 37); activated caspase 8 further cleaves downstream effector caspases.”
BackgroundModulation of apoptosis and Bcl-2 expression by prostaglandin E2 in human colon cancer cells.
Sheng, H., Shao, J., Morrow, J. D., Beauchamp, R. D., & Dubois, R. N. (1998) · PubMed · Cited by 1,236
Research works printed but not linked: 2
- 10.1172/jci22218 · doi:10.1172/jci22218 · Paper page
- 10.1002/(sici)1521-4141(199907)29:07<2360::aid-immu2360>3.0.co;2-a · doi:10.1002/(sici)1521-4141(199907)29:07<2360::aid-immu2360>3.0.co;2-a
Cited by
Items 101–152 of 152
Talukder, J. R., Griffin, A., Jaima, A., Boyd, B., & Wright, J. (2013) · Canadian Journal of Physiology and Pharmacology · doi:10.1139/cjpp-2013-0211 · Cited by 14
“PGE2 has been shown to be apoptotic in fibroblast (Huang et al. 2009) and anti-apoptotic in multiple cell types including normal epithelial cells (Tessner et al.”
BackgroundHsu, Y., Cheng, C., Chen, Y.-C., Chen, T.-H., Sue, Y., Tsai, W.-L., & Chen, C. (2012) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2012.06.008 · Cited by 14
Baird, A., Lloyd, F., & Lawrance, I. C. (2015) · Digestive Diseases and Sciences · doi:10.1007/s10620-015-3552-9 · Cited by 14
“It inhibits fibroblast proliferation, migration, and differentiation into myofibroblasts, collagen synthesis, and induces lung fibroblast apoptosis via the activation of the E prostanoid 2 and 4 receptors [8, 13].”
Yu, D., Zhuang, Z., Ren, J., Hu, X., Wang, Z., Zhang, J., Luo, Y., Wang, K., He, R., & Wang, Y. (2019) · Regenerative Biomaterials · doi:10.1093/rb/rbz016 · Cited by 15
Mechanistic basis for the antifibrotic actions of cAMP-based therapies
Peters-Golden, M. L., & Fortier, S. M. (2026) · European Respiratory Review · doi:10.1183/16000617.0265-2025 · Cited by 13
“At the same time, elevation of cAMP promotes fibroblast apoptosis [61] and collagen degradation [62].”
Self-citationVenter, C., Myburgh, K. H., & Niesler, C. U. (2021) · Physiological Reports · doi:10.14814/phy2.14704 · Cited by 13
“Since M1 macrophage-secreted factors can result in myofibroblast death (Huang et al., 2009; Humphreys & Wilson, 1999; Nascimento et al., 2015), the prolonged presence of M1 macrophages would negatively impact myoblast differentiation and fusion and other myofibroblast functions in the late phases of regeneration, such…”
BackgroundInfluentialKovářová, M., & Koller, B. H. (2014) · PLoS ONE · doi:10.1371/journal.pone.0102948 · Cited by 11
“Several previous reports have described the ability of PGE2 to either potentiate cell death [28,41,42] or protect against it [43,44].”
BackgroundEP4: a new piece in the fibrotic puzzle
Boor, P. (2012) · Kidney International · doi:10.1038/ki.2012.125 · Cited by 11
Reimagining Fibrosis Research, Outcomes, and Therapeutics Through the Lens of Resolution
Fortier, S. M., Redente, E. F., & Peters-Golden, M. L. (2025) · Seminars in Respiratory and Critical Care Medicine · doi:10.1055/a-2666-7479 · Cited by 11
Self-citationHuman airway trypsin‐like protease exerts potent, antifibrotic action in pulmonary fibrosis
Menou, A., Flajolet, P., Duitman, J., Justet, A., Moog, S., Jaillet, M., Tabèze, L., Solhonne, B., Garnier, M., Mal, H., et al. (2017) · The FASEB Journal · doi:10.1096/fj.201700583r · Cited by 10
Intracellular prostaglandin E2 contributes to hypoxia-induced proximal tubular cell death
García-Pastor, C., Martínez, S. B., Bosch, R. J., Fernández‐Martínez, A. B., & Lucio-Cazaña, F. J. (2021) · Scientific Reports · doi:10.1038/s41598-021-86219-w · Cited by 10
Wang, Y., Goodman, C. L., Ringbauer, J. A., Li, Y., & STANLEY, D. W. (2021) · Archives of Insect Biochemistry and Physiology · doi:10.1002/arch.21844 · Cited by 11
Following the Path of CCL2 from Prostaglandins to Periostin in Lung Fibrosis
Moore, B. B. (2014) · American Journal of Respiratory Cell and Molecular Biology · doi:10.1165/rcmb.2014-0075ps · Cited by 8
“Normally, PGE2 signaling can induce fibroblast apoptosis (36), but when fibroblasts encounter stiffened extracellular matrix, their ability to generate antifibrotic PGE2 is suppressed (37, 38).”
BackgroundShi, H., Wang, X., Li, X., & Feng, Y. (2025) · Dermatologic Therapy · doi:10.1155/dth/9950475 · Cited by 8
Baas, J. D., Varga, J., Feghali‐Bostwick, C. A., Peters-Golden, M. L., & Fortier, S. M. (2025) · The FASEB Journal · doi:10.1096/fj.202500694rr · Cited by 7
Self-citationLung carcinogenesis and fibrosis taken together: just coincidence?
Giopanou, I., Arendt, K. A. M., & Stathopoulos, G. T. (2017) · Current Opinion in Pulmonary Medicine · doi:10.1097/mcp.0000000000000390 · Cited by 7
Prostaglandin E2's New Trick: “Decider” of Differential Alveolar Cell Life and Death
Horowitz, J. C., & Peters-Golden, M. L. (2010) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201002-0239ed · Cited by 7
Self-citationRiancho, J., Gil-Bea, F. J., Vázquez, D. C., Sedano, M. J., Zufiría, M., Fernández‐Eulate, G., Poza, J. J., & de Munaín, A. L. (2018) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2018.08.013 · Cited by 6
Lee, J., Martínez, N., West, K., & Kornfeld, H. (2015) · PLoS ONE · doi:10.1371/journal.pone.0123165 · Cited by 6
Outstaying their Welcome: The Persistent Myofibroblast in IPF.
Huang, S. K., & Horowitz, J. C. (2014) · PubMed · Cited by 10
Self-citationMohning, M. P., Downey, G. P., Cosgrove, G. P., & Redente, E. F. (2018) · Elsevier eBooks · doi:10.1016/b978-0-323-54431-3.00003-2 · Cited by 122
Lipidmediatoren und ihre Rolle bei Entzündungen und Allergien
Stockert, K. (2020) · Springer eBooks · doi:10.1007/978-3-662-58140-7_6 · Cited by 6
“PGE2 fördert 5 die Apoptose der Fibroblasten (Huang et al.”
BackgroundCottin, V., Valenzuela, C., & Humbert, M. J. C. (2023) · European Respiratory Journal · doi:10.1183/13993003.00944-2023 · Cited by 6
Mohan, K., Ntambi, J. M., & Moussaieff, A. (2026) · Journal of Lipid Research · doi:10.1016/j.jlr.2026.101036 · Cited by 3
“These prostaglandins also down-regulate key survival pathways, including the phosphatidylinositol 3-kinase (PI3K)/protein kinase B (PKB/Akt) signaling cascade (125), and the nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κ B) signaling pathway (126).”
Zuntini, A. C. S., Damico, M. V., Gil, C. D., Godinho, R. O., Pacini, E. S. A., Fortes-Dias, C. L., & Moreira, V. (2023) · Toxicology and Applied Pharmacology · doi:10.1016/j.taap.2023.116384 · Cited by 3
Plakoglobin expression in fibroblasts and its role in idiopathic pulmonary fibrosis
Matthes, S. A., LaRouere, T. J., Horowitz, J. C., & White, E. S. (2015) · BMC Pulmonary Medicine · doi:10.1186/s12890-015-0137-5 · Cited by 3
“Since prior data suggests a role for plakoglobin in mediating apoptosis [29, 30], we next transfected primary normal or IPF fibroblasts with siRNA-PG or ΦsiRNA constructs followed by induction of apoptosis using a Fas-activating antibody and cycloheximide for 6 hours (N = 16 for both normal and IPF cells transfected w…”
MethodSelf-citation“Yap”-ing about the Antifibrotic Benefits of Prostacyclin
Huang, S. K. (2018) · American Journal of Respiratory Cell and Molecular Biology · doi:10.1165/rcmb.2018-0392ed · Cited by 3
“PGE2 inhibits all aspects of fibroblast function, including matrix production, fibroblast survival (4) and proliferation (5), and myofibroblast differentiation (6).”
BackgroundSelf-citationMolina, T., Fabre, P., Garcia, P., Taeyeon, K., Gurlekian, Z., Tellier, L., Rieger, L., Dallaire, J., Collette, É., Desaulniers, R., et al. (2026) · Cell Death and Differentiation · doi:10.1038/s41418-026-01762-1 · Cited by 2
Prostaglandin E2 exerts the proapoptotic and antiproliferative effects on bovine NK cells
Maślanka, T., Chrostowska, M., Otrocka‐Domagała, I., Snarska, A., Mikiewicz, M., Zuśka-Prot, M., Jasiecka-Mikołajczyk, A., Ziółkowski, H., Markiewicz, W., & JAROSZEWSKI, J. J. (2016) · Research in Veterinary Science · doi:10.1016/j.rvsc.2016.05.009 · Cited by 2
Interstitial lung disease-associated pulmonary hypertension – what the future holds
Cottin, V., Diesler, R., Turquier, S., & Valenzuela, C. (2023) · Current Opinion in Pulmonary Medicine · doi:10.1097/mcp.0000000000000992 · Cited by 2
Fibroblast Cyclooxygenase 2 Expression in the Development of Progressive Kidney Fibrosis
Tsai, M., Jiang, M., Pan, Y., Cao, S., Wang, Y., Chen, J., Li, S., Dong, X., Luo, W., Fogo, A. B., et al. (2026) · Journal of the American Society of Nephrology · doi:10.1681/asn.0000001218 · Cited by 1
Talukder, J. R., & Wright, J. (2015) · Journal of Gastrointestinal & Digestive System · doi:10.4172/2161-069x.1000364 · Cited by 1
“It has been shown that the blockade of the LTB4-signaling pathway induces apoptosis via the inhibition of ERK activation in colon cancer cells [13].”
BackgroundCellular and Molecular Mechanisms of Fibrosis in Systemic Sclerosis
Trojanowska, M., Varga, J., & Lagares, D. (2024) · Springer eBooks · doi:10.1007/978-3-031-40658-4_18 · Cited by 2
Superficial Dermal and Fascial Fibromatoses
Yvon, A., Volk, S. W., & Bayat, A. (2014) · Elsevier eBooks · doi:10.1016/b978-0-12-386456-7.04403-8 · Cited by 1
A case of primary malignant hemangiopericytoma of the heart with fatal outcome.
Ghiribelli, C., Campione, A., Ligabue, T., Biscéglie, M. D., Severi, S., Gentilini, R., & Gotti, G. (2006) · PubMed · Cited by 1
Modulação da morte mediada por FAS em células tipo I e tipo II.
Medina, L. P. (2011) · Digital Library of Theses and Dissertations (Universidade de São Paulo) · doi:10.11606/d.42.2011.tde-09022012-123037 · Cited by 2
PAPEL ANTI-FIBRÓTICO DE PGE2 E BMP-7 NA ASMA ALÉRGICA EXPERIMENTAL
Jancar, S. (2012)
Endometrial changes induced by prostaglandin E2 and EP4 receptor agonist in albino rats
El-Nefiawy, N. E. (2011) · The Egyptian Journal of Histology · doi:10.1097/01.ehx.0000396642.87633.92
Role of Proteases in Idiopathic Pulmonary Fibrosis
Chatterjee, S., Chakraborty, K., Moitra, S., & Bhattacharyya, A. (2017) · Springer eBooks · doi:10.1007/978-981-10-6141-7_22
BH3 Mimetic Drugs for Anti-fibrotic Therapy
Lagares, D. (2020) · Royal Society of Chemistry eBooks · doi:10.1039/9781788015783-00235
Stewart, A. G., Soon, L., & Schuliga, M. J. (2011) · Wiley eBooks · doi:10.1002/9781444346688.ch11
Selige, J. (2010) · KOPS (University of Konstanz)
Metabolic Profiling Reveals Insights Into Bladder Cancer Pathogenesis and Recurrence
Saygın, H., Bolat, S., Kablan, D., Yavuz, H., Kurt, M. A., Kır, A., Öztürk, A., Doğan, A., Şenol, O., Doğan, H. O., et al. (2026) · Advances in Urology · doi:10.1155/aiu/6524384
Gagliolo, J. (2013) · theses.fr (ABES) · doi:10.70675/84af498cze206z4d3dzb4e4z06e84bafbe0a
Ngangue, E. C.-N. (2012) · theses.fr (ABES) · doi:10.70675/b9e28642z5037z4fceza4d6za62be310d18d · Cited by 1
“Ce phénomène appelé paradoxe apoptotique pourrait être relié à la diminution de la production de PGE2 observé au cours de la FPI (Maher et al. 2010; Huang et al. 2009) .”
BackgroundImplication de FGF9 et de FGF19 dans la fibrose pulmonaire idiopathique
Justet, A. (2020) · theses.fr (ABES) · doi:10.70675/6e72f095z0cb6z4dd3zb204z88d1b08b9910
The emerging role of PDE4 inhibitors for the treatment of pulmonary fibrosis
Tyker, A., Kuse, N., Pertzov, B., & Kolb, M. R. (2026) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2026.2737175
Speth, J. M., Wong, V. T., Guzman, S. D., Walker, N., Liu, Y., Zemans, R. L., Blackwell, T. S., Aguilar, C. A., Peters-Golden, M. L., & Fortier, S. M. (2026) · Scientific Reports · doi:10.1038/s41598-026-75301-w · Cited by 1
“K ) Longitudinal GSEA of HGF/MET ( I ), cAMP ( J ), and FasL/CD95L ( K ) signaling pathways in alveolar and adventitial fibroblasts.”
InfluentialSelf-citation
Metadata
- Authors
- Huang, S. K., White, E. S., Wettlaufer, S. H., Grifka, H., Hogaboam, C. M., Thannickal, V. J., Horowitz, J. C., & Peters-Golden, M.
- Affiliations
- University of Michigan (US)
- Division of Pulmonary and Critical Care Medicine Department of Internal Medicine University of Michigan Medical School Ann Arbor Michigan USA
- ORCID
- Venue
- The FASEB Journal
- Publisher
- Wiley
- Published
- 2009-08-11
- Volume
- 23
- Issue
- 12
- Pages
- 4317-4326
- ISSN
- 0892-6638 (ISSN-L)
- 1530-6860
- PMC
- PMC2812040
- OpenAlex
- W2133907923
- Cited by
- 147
- References
- 59
- Citations by year
- 2026: 5 · 2025: 4 · 2024: 3 · 2023: 6 · 2022: 8 · 2021: 12 · 2020: 7 · 2019: 7 · 2018: 13 · 2017: 5 · 2016: 8 · 2015: 15 · 2014: 12 · 2013: 10 · 2012: 11
- FWCI
- 7.45
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- The FASEB Journal (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Deep Blue (University of Michigan) (submittedVersion)
- Funders
- National Institutes of Health (P50 HL56402)
- National Heart, Lung, and Blood Institute
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Inflammatory mediators and NSAID effects
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Cell death mechanisms and regulation
- Keywords
- prostaglandin E2, fibroblast apoptosis, lung fibroblasts, pulmonary fibrosis, EP2 receptor, EP4 receptor, caspase-8, caspase-9, PTEN, Akt signaling, survivin, Fas ligand, interstitial lung disease, fibrogenesis
- MeSH terms
- Cell Line, Fibroblasts, Gene Expression Regulation, Humans, Lung, Dinoprostone, Signal Transduction, Apoptosis, PTEN Phosphohydrolase
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.